Abstract
The selection criteria for a new drug to be used in the treatment of arterial hypertension or angina pectoris may be somewhat different for the two conditions. In hypertension, which is usually an asymptomatic condition, the primary aim of treatment is to reduce cardiovascular morbidity and mortality. A secondary aim may be to reverse hypertension-induced cardiovascular hypertrophy, whereas the third and most common aim is simply to lower blood pressure. In angina pectoris, by definition a symptomatic condition, the primary therapeutic goal is to abolish or prevent pain and distress. In both conditions the effectiveness with which the therapeutic aim is obtained must be set against the adverse effects caused by treatment. In addition, other factors, such as the effects on serum lipoproteins, the duration of action and the extent to which the patient's well-being is affected by treatment must also be considered. New compounds developed for the treatment of arterial hypertension and angina pectoris must be evaluated against this background. The new β-adrenoceptor blocking compound bopindolol seems to meet the requirements described.